Natural Killer/T-cell Lymphoma Clinical Trials

3 recruiting

Natural Killer/T-cell Lymphoma Trials at a Glance

7 actively recruiting trials for natural killer/t-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Beijing, Fuzhou, and Guangzhou. Lead sponsors running natural killer/t-cell lymphoma studies include Fudan University, Baylor College of Medicine, and Beijing Tongren Hospital.

Browse natural killer/t-cell lymphoma trials by phase

Treatments under study

About Natural Killer/T-cell Lymphoma Clinical Trials

Looking for clinical trials for Natural Killer/T-cell Lymphoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Natural Killer/T-cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Natural Killer/T-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sun Yat-sen University84 enrolled1 locationNCT06583083
Recruiting
Phase 2

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Fudan University210 enrolled7 locationsNCT06314334
Recruiting
Phase 2

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Natural Killer/T-cell Lymphoma
Ruijin Hospital47 enrolled1 locationNCT07380984
Recruiting
Phase 1

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin LymphomaExtranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Baylor College of Medicine18 enrolled2 locationsNCT04288726
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Natural Killer/T-cell LymphomaRelapsed or Refractory Lymphoma Including ENKL
Fudan University68 enrolled1 locationNCT06966154
Recruiting
Phase 1Phase 2

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

T-lymphoblastic LymphomaNatural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Beijing Tongren Hospital43 enrolled1 locationNCT06376721
Recruiting
Phase 2

Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Natural Killer/T-cell LymphomaRelapsed Natural Killer/T-cell LymphomaRefractory Natural Killer/T-cell Lymphoma
Won Seog Kim37 enrolled1 locationNCT04763616